@article{10.11648/j.ijcd.20260902.13,
  author = {Yannick Quesnel and Michael Gold},
  title = {Glucuronyl Glucosyloleanolate, an AI-Discovered Saponin: From Melanocyte Assays to Clinical Skin 
Lightening-Brightening in a Multi-Ethnic Panel},
  journal = {International Journal of Clinical Dermatology},
  volume = {9},
  number = {2},
  pages = {118-131},
  doi = {10.11648/j.ijcd.20260902.13},
  url = {https://doi.org/10.11648/j.ijcd.20260902.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcd.20260902.13},
  abstract = {Most of the depigmenting active ingredients currently in use work by inhibiting the catalytic activity of tyrosinase, and several of them are now subject to increasingly stringent regulatory and tolerance requirements. Glucuronylglucosyloleanolate (GGO), a natural triterpene saponin, was identified from public compound databases using an AI-based discovery platform combining in-silico predictions, physchem parameters and market requirements; and was subsequently subjected to a series of stepwise experiments. In normal human epidermal melanocytes, GGO reduced melanin production by up to 86% at a concentration of 2 µg/mL without any loss of viability; in one benchmark, it scored ahead of hydroquinone, kojic acid, niacinamide and tranexamic acid on melanin reduction. An in vitro assay on melanocyte tyrosinase showed no inhibition between 0.3 and 100 µM, indicating that the compound acts on enzyme expression rather than catalysis, and that it may also interfere with melanosome transfer. In UV-stimulated human explants, melanin content decreased by 45% and tyrosinase expression was reduced by a factor of 2.4 compared with controls, whilst tissue integrity was preserved. Safety was assessed at three levels: a 48-hour semi-occlusive patch test with the pure compound on 12 volunteers yielded an average irritation index of 0.00; the validated GARD®skin test revealed no sensitizing potential up to 0.4 g/L; and a repeated-challenge test in humans (HRIPT), carried out on over 100 volunteers at a concentration ten times higher than the clinical dose, did not result in any irritant or allergic reactions. Clinical efficacy was assessed in a randomized, single-blind, placebo-controlled trial, in which 60 volunteers, stratified according to Fitzpatrick phototype, applied 0.01% GGO or a placebo twice daily for 84 days. The individual typology angle increased significantly from day 21 onwards and continued to rise until day 84, reaching 11% in phototype III, 14% in phototype IV and 24% in phototype V, with no plateau observed at the end of the study. Hyperpigmented spots responded earlier and more rapidly than the surrounding skin, lightening approximately 34% faster to achieve a 17% reduction in patch intensity by day 84 and a measurable reduction in contrast compared with the adjacent skin. GGO therefore reduces the expression of enzymes involved in melanogenesis, a mechanism distinct from that of ingredients currently on the market, while also restricting pigment distribution, an effect reported in the literature. GGO achieves clinically significant depigmentation of both the overall complexion and localized hyperpigmentation at a concentration of 0.01%, making it far more potent than all competing products.},
 year = {2026}
}

Copy | Download

TY  - JOUR
T1  - Glucuronyl Glucosyloleanolate, an AI-Discovered Saponin: From Melanocyte Assays to Clinical Skin 
Lightening-Brightening in a Multi-Ethnic Panel
AU  - Yannick Quesnel
AU  - Michael Gold
Y1  - 2026/09/29
PY  - 2026
N1  - https://doi.org/10.11648/j.ijcd.20260902.13
DO  - 10.11648/j.ijcd.20260902.13
T2  - International Journal of Clinical Dermatology
JF  - International Journal of Clinical Dermatology
JO  - International Journal of Clinical Dermatology
SP  - 118
EP  - 131
PB  - Science Publishing Group
SN  - 2995-1305
UR  - https://doi.org/10.11648/j.ijcd.20260902.13
AB  - Most of the depigmenting active ingredients currently in use work by inhibiting the catalytic activity of tyrosinase, and several of them are now subject to increasingly stringent regulatory and tolerance requirements. Glucuronylglucosyloleanolate (GGO), a natural triterpene saponin, was identified from public compound databases using an AI-based discovery platform combining in-silico predictions, physchem parameters and market requirements; and was subsequently subjected to a series of stepwise experiments. In normal human epidermal melanocytes, GGO reduced melanin production by up to 86% at a concentration of 2 µg/mL without any loss of viability; in one benchmark, it scored ahead of hydroquinone, kojic acid, niacinamide and tranexamic acid on melanin reduction. An in vitro assay on melanocyte tyrosinase showed no inhibition between 0.3 and 100 µM, indicating that the compound acts on enzyme expression rather than catalysis, and that it may also interfere with melanosome transfer. In UV-stimulated human explants, melanin content decreased by 45% and tyrosinase expression was reduced by a factor of 2.4 compared with controls, whilst tissue integrity was preserved. Safety was assessed at three levels: a 48-hour semi-occlusive patch test with the pure compound on 12 volunteers yielded an average irritation index of 0.00; the validated GARD®skin test revealed no sensitizing potential up to 0.4 g/L; and a repeated-challenge test in humans (HRIPT), carried out on over 100 volunteers at a concentration ten times higher than the clinical dose, did not result in any irritant or allergic reactions. Clinical efficacy was assessed in a randomized, single-blind, placebo-controlled trial, in which 60 volunteers, stratified according to Fitzpatrick phototype, applied 0.01% GGO or a placebo twice daily for 84 days. The individual typology angle increased significantly from day 21 onwards and continued to rise until day 84, reaching 11% in phototype III, 14% in phototype IV and 24% in phototype V, with no plateau observed at the end of the study. Hyperpigmented spots responded earlier and more rapidly than the surrounding skin, lightening approximately 34% faster to achieve a 17% reduction in patch intensity by day 84 and a measurable reduction in contrast compared with the adjacent skin. GGO therefore reduces the expression of enzymes involved in melanogenesis, a mechanism distinct from that of ingredients currently on the market, while also restricting pigment distribution, an effect reported in the literature. GGO achieves clinically significant depigmentation of both the overall complexion and localized hyperpigmentation at a concentration of 0.01%, making it far more potent than all competing products.
VL  - 9
IS  - 2
ER  - 

Copy | Download